JP7278593B2 - 外傷性脳損傷のためのグリセリル３－ヒドロキシブチラート - Google Patents

外傷性脳損傷のためのグリセリル３－ヒドロキシブチラート Download PDF

Info

Publication number
JP7278593B2
JP7278593B2 JP2019536598A JP2019536598A JP7278593B2 JP 7278593 B2 JP7278593 B2 JP 7278593B2 JP 2019536598 A JP2019536598 A JP 2019536598A JP 2019536598 A JP2019536598 A JP 2019536598A JP 7278593 B2 JP7278593 B2 JP 7278593B2
Authority
JP
Japan
Prior art keywords
hydroxybutyrate
glyceryl
tbi
ester
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019536598A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504134A (ja
JP2020504134A5 (enExample
Inventor
ハシム、サミ
Original Assignee
ニューロエナジー ベンチャーズ、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューロエナジー ベンチャーズ、インコーポレイテッド filed Critical ニューロエナジー ベンチャーズ、インコーポレイテッド
Publication of JP2020504134A publication Critical patent/JP2020504134A/ja
Publication of JP2020504134A5 publication Critical patent/JP2020504134A5/ja
Application granted granted Critical
Publication of JP7278593B2 publication Critical patent/JP7278593B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019536598A 2017-01-12 2017-11-30 外傷性脳損傷のためのグリセリル３－ヒドロキシブチラート Active JP7278593B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/404,396 2017-01-12
US15/404,396 US9925164B1 (en) 2017-01-12 2017-01-12 Glyceryl 3-hydroxybutyrates for traumatic brain injury
PCT/US2017/063853 WO2018132189A1 (en) 2017-01-12 2017-11-30 Glyceryl 3-hydroxybutyrates for traumatic brain injury

Publications (3)

Publication Number Publication Date
JP2020504134A JP2020504134A (ja) 2020-02-06
JP2020504134A5 JP2020504134A5 (enExample) 2021-01-14
JP7278593B2 true JP7278593B2 (ja) 2023-05-22

Family

ID=61633011

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019536598A Active JP7278593B2 (ja) 2017-01-12 2017-11-30 外傷性脳損傷のためのグリセリル３－ヒドロキシブチラート

Country Status (11)

Country Link
US (3) US9925164B1 (enExample)
EP (1) EP3568129A4 (enExample)
JP (1) JP7278593B2 (enExample)
KR (1) KR102443942B1 (enExample)
CN (1) CN110114067A (enExample)
BR (1) BR112019014128A2 (enExample)
CA (1) CA3046355C (enExample)
IL (1) IL267934B2 (enExample)
MX (1) MX391851B (enExample)
MY (1) MY207193A (enExample)
WO (1) WO2018132189A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
SG11201809211QA (en) * 2016-04-19 2018-11-29 Keto Patent Group Inc Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12622889B2 (en) 2016-04-19 2026-05-12 Axcess Global Sciences, Llc S-β-hydroxybutyrate esters for improving metabolic function
US10376528B2 (en) 2017-03-10 2019-08-13 Tecton Group, Llc Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor
US12171735B2 (en) 2017-04-19 2024-12-24 Axcess Global Sciences, Llc Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
GB201715654D0 (en) 2017-09-27 2017-11-08 Tdeltas Ltd Method of treatment
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
WO2020147978A1 (de) * 2019-01-17 2020-07-23 Ioi Oleo Gmbh Verfahren zur herstellung von glyceriden von hydroxycarbonsäuren
ES2965646T3 (es) * 2019-01-17 2024-04-16 Ketolipix Therapeutics Gmbh Procedimiento para la producción de lípidos que contienen unidades estructurales a base de glicéridos de ácidos hidroxicarboxílicos
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
CN113710243A (zh) * 2019-05-30 2021-11-26 神经活力投资公司 甘油三(β-羟基丁酸酯)与神经元短暂性脑缺血发作
ES2969217T3 (es) * 2019-06-12 2024-05-17 Ketolipix Therapeutics Gmbh Procedimiento para la producción de ésteres a base de poliol, en particular ésteres de poliglicerol, de ácidos hidroxicarboxílicos
CN113966323B (zh) * 2019-06-12 2023-11-28 凯托利皮克斯治疗有限责任公司 一种用于生产酮羧酸多元醇基酯的方法
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
EP4146337B1 (de) * 2020-07-13 2024-04-17 KetoLipix Therapeutics GmbH Verfahren zur herstellung von polyglycerinestern von mit oxobutanol veresterten polycarbonsäuren
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
WO2023283654A1 (en) * 2021-07-09 2023-01-12 Georgia State University Research Foundation, Inc. The use of beta-hydroxybutyrates for the treatment or prevention of aneurysms and dissections
AU2022387742A1 (en) 2021-11-12 2024-06-27 Arxada Ag Polyol-derived compounds
WO2023094654A1 (en) 2021-11-26 2023-06-01 Arxada Ag Acetoacetate based ketals
US12023382B2 (en) 2022-01-18 2024-07-02 Today Inc. Molecules, formulations, and methods for nutritional support of athletes, patients, and others
WO2023139357A1 (en) * 2022-01-18 2023-07-27 Today Inc. Molecules, nutritional formulations, and methods of providing nutritional support
US20230277484A1 (en) * 2022-03-04 2023-09-07 Guardian Biosciences, LLC Compositions and methods to promote brain health
EP4605371A1 (en) 2022-10-18 2025-08-27 Arxada AG Polyol-derived compounds
WO2025074001A2 (en) 2023-10-05 2025-04-10 Arxada Ag Enzymatic reduction of acetoacetate
WO2025196156A1 (en) 2024-03-20 2025-09-25 Arxada Ag Continuous hydrogenation process of acetoacetate esters
WO2025224319A1 (en) 2024-04-25 2025-10-30 Arxada Ag Reduction of acetoacetate esters in the presence of amines
WO2026090272A1 (en) * 2024-10-23 2026-04-30 2508 Biosciences Llc Methods and compositions for the treatment of disease

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4598203B2 (ja) 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
US6323237B1 (en) 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
CN1315473C (zh) * 1997-03-17 2007-05-16 英国技术集团国际有限公司 治疗组合物
US8124589B2 (en) 2000-05-01 2012-02-28 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
GB0420856D0 (en) * 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
CN103505728A (zh) 2005-05-26 2014-01-15 科罗拉多大学评议会法人机构 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制
WO2008005818A1 (en) * 2006-06-30 2008-01-10 Stepan Co Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
CA2684213A1 (en) 2007-04-12 2008-10-23 Regents Of The University Of Minnesota Ischemia/reperfusion protection compositions and methods of using
JP2009173766A (ja) 2008-01-24 2009-08-06 Ono Kogei Kk 炭素繊維含有コーティング組成物およびその調製方法
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
AU2010207597A1 (en) 2009-01-24 2011-08-18 Phytopharm Plc Treatment of neurotrophic factor mediated disorders
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
CA2873057C (en) 2011-05-09 2020-02-25 University Of South Florida The use of ketone esters for prevention of cns oxygen toxicity
US20140072654A1 (en) 2011-12-23 2014-03-13 Savind, Inc. Cancer with metabolic therapy and hyperbaric oxygen
FR2997302B1 (fr) 2012-10-29 2015-02-06 Assist Publ Hopitaux De Paris Prevention et traitement des deficits en pyruvate deshydrogenase
WO2014071389A1 (en) 2012-11-05 2014-05-08 Veech Richard L Ketone bodies to protect tissues from damage by ionizing radiation
EP2925308B1 (en) 2012-11-28 2019-12-25 University Of South Florida Targeting cancer with metabolic therapy and hyperbaric oxygen
BR112015024186B1 (pt) 2013-03-19 2023-05-09 University Of South Florida Composições e métodos para produção de cetose de elevação e manutenção
WO2015034812A2 (en) * 2013-09-04 2015-03-12 Beth Israel Deaconess Medical Center A new ketogenic diet and its use in treating the critically ill
CA2973342A1 (en) 2014-01-13 2015-10-15 University Of South Florida Methods of sustaining dietary ketosis and its effects on lipid profile
US20160078782A1 (en) 2014-09-17 2016-03-17 The Trustees Of Boston College Glucose Ketone Index for MetabolicTherapy
US9364456B1 (en) 2015-06-30 2016-06-14 University Of South Florida Ketone esters for treatment of angelman syndrome
US20180200220A1 (en) 2015-07-10 2018-07-19 Cognate Nutritionals, Inc. Prophylaxis and mitigation of migraine headaches using ketogenic medium chain triglycerides, ketone esters, and other ketogenic sources
US10292952B2 (en) 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US20190091189A1 (en) 2016-03-21 2019-03-28 Csilla Ari D'Agostino Administration of exogenous ketone to lower blood glucose
US10376482B2 (en) 2016-04-03 2019-08-13 Franco Cavaleri Butyrate and beta-hydroxybutyrate compositions
SG11201809211QA (en) 2016-04-19 2018-11-29 Keto Patent Group Inc Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
WO2018009208A1 (en) 2016-07-08 2018-01-11 Cognate Nutritionals, Inc. Nutritional mitiggation of the cns effects of traumatic brain injury
US10588877B2 (en) 2016-07-21 2020-03-17 Savind, Inc. Compositions comprising β-hydroxybutyric acid and salt, and methods of using the same
US20180057846A1 (en) 2016-08-30 2018-03-01 KetoneAid Inc. Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy
US20180055797A1 (en) 2016-08-31 2018-03-01 KetoneAid Inc. Non-racemic ketone salts for rapid-onset nutritional ketosis and metabolic therapy
JP2019526607A (ja) 2016-09-12 2019-09-19 ユニバーシティ・オブ・サウス・フロリダ ケトンにより改善された神経再生

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IUBMB Life，2012年，Vol.64, No.2，pp.203-207

Also Published As

Publication number Publication date
IL267934B1 (en) 2024-05-01
MY207193A (en) 2025-02-05
KR20190104546A (ko) 2019-09-10
CN110114067A (zh) 2019-08-09
JP2020504134A (ja) 2020-02-06
US9925164B1 (en) 2018-03-27
US11638702B2 (en) 2023-05-02
MX2019008269A (es) 2019-09-13
US10736867B2 (en) 2020-08-11
CA3046355C (en) 2023-08-01
IL267934B2 (en) 2024-09-01
KR102443942B1 (ko) 2022-09-15
IL267934A (en) 2019-09-26
WO2018132189A1 (en) 2018-07-19
EP3568129A4 (en) 2020-12-09
US20180193300A1 (en) 2018-07-12
CA3046355A1 (en) 2018-07-19
US20200297686A1 (en) 2020-09-24
MX391851B (es) 2025-03-21
BR112019014128A2 (pt) 2020-06-16
EP3568129A1 (en) 2019-11-20

Similar Documents

Publication Publication Date Title
US11638702B2 (en) Glyceryl 3-hydroxybutyrates for traumatic brain injury
JP7108320B2 (ja) 片頭痛の症状を管理するためのグリセリル３－ヒドロキシブチラート
JP2020504134A5 (enExample)
McEldrew et al. Vitamin a
US5866555A (en) Diabetic supplement bar
Wang et al. Analysis of risk factors for parenteral nutrition-associated cholestasis in preterm infants: a multicenter observational study
JP2000509258A (ja) 糖尿病用補足バー
RS20050226A (sr) EIKOSAPENTAENOIČNA KISELINA (EPA) ZA LEČENjE ANOREXIA NERVOSA I BULIMIJE
Vining The ketogenic diet
Haglind et al. Growth in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency
Keskin et al. Protein substitutions as new-generation pharmanutrition approach to managing phenylketonuria
JP7847432B2 (ja) 食後血糖応答を制御するための乳清タンパク質ミセルの使用
Phillips Ketogenic diet therapies in children and adults with epilepsy
Stepien et al. The Challenges of a Successful Pregnancy in a Patient with Adult Refsum’s Disease due to Phytanoyl-CoA Hydroxylase Deficiency
AMATUZIO et al. Dietary Control of Essential Hyperlipemia: Effect of Dairy Foods, Phospholipid, Coconut Oil, and Alcohol
Kuźniar et al. Ketogenic diet and intermittent fasting-impact on body weight and various diseases
Rosyid et al. Effectiveness of Zinc Therapy with Zinc-Probiotic Combination Therapy on the Duration of Diarrhea During Hospitalization at Mawaddah Medika Hospital in October-December 2023
WO2013005834A1 (ja) 高純度ｅｐａを含有する抗肥満剤
HK40012461A (en) Glyceryl 3-hydroxybutyrates for traumatic brain injury
Kreymann et al. Intensive medicine–Guidelines on Parenteral Nutrition, Chapter 14
Nightingale et al. Nutritional optic and peripheral neuropathy: a case report
Price Parenteral nutrition
Sato et al. Effects of Oral Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Body Weight in Two Adult Patients with Down Syndrome and Type 2 Diabetes: A Case Report
Jung et al. The weight reduction effect of yeast hydrolysate-SR101 on female college students
Mohammed et al. Successful Management of Severe Hypertriglyceridemia in a Neonate with Apolipoprotein A Deficiency: A Case Report with Literature Review

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A525

Effective date: 20190704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221013

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230215

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230216

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230308

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230309

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230418

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230428

R150 Certificate of patent or registration of utility model

Ref document number: 7278593

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250